QuVa Pharma Teams Up with Premier to Enhance Drug Diversion Prevention
QuVa Pharma and Premier: A New Leap in Drug Diversion Prevention
QuVa Pharma, a leader in outsourced sterile injectable compounding services, has taken a significant step forward in healthcare safety by securing a national group purchasing agreement for Drug Diversion Software Solutions with Premier, Inc. This strategic partnership, effective May 1, 2026, marks a crucial alignment in the fight against drug diversion, which is increasingly becoming a pressing issue within healthcare systems.
The Need for Advanced Drug Diversion Solutions
The healthcare industry faces mounting pressure to protect controlled substances and ensure the safety of both patients and healthcare professionals. With rising incidents of drug misuse, there is an urgent need for technology that not only detects possible discrepancies but also aids in compliance and appropriate resource allocation. QuVa's CEO and Co-Founder, Stuart Hinchen, highlighted this partnership's importance:
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.